Dodge & Cox
NBIX icon

Dodge & Cox’s Neurocrine Biosciences NBIX Stock Holding History

Dodge & Cox’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$941M Buy
5,584,707
+123,670
+2% +$18.3M 0.49% 69
2026
Q1 		$719M Sell
5,461,037
-47,005
-0.9% -$6.24M 0.4% 74
2025
Q4 		$781M Sell
5,508,042
-48,576
-0.9% -$7.04M 0.42% 68
2025
Q3 		$780M Sell
5,556,618
-10,196
-0.2% -$1.38M 0.42% 73
2025
Q2 		$700M Buy
5,566,814
+32,190
+0.6% +$3.69M 0.39% 68
2025
Q1 		$612M Buy
5,534,624
+2,518,199
+83% +$319M 0.35% 77
2024
Q4 		$412M Buy
3,016,425
+1,728,605
+134% +$214M 0.24% 84
2024
Q3 		$148M Buy
1,287,820
+7,000
+0.5% +$960K 0.08% 94
2024
Q2 		$176M Buy
1,280,820
+15,576
+1% +$2.14M 0.11% 90
2024
Q1 		$175M Buy
1,265,244
+5,500
+0.4% +$751K 0.1% 91
2023
Q4 		$166M Buy
1,259,744
+1,046,142
+490% +$120M 0.11% 90
2023
Q3 		$24M Buy
+213,602
New +$22.5M 0.02% 106

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Dodge & Cox's NBIX Position: Q2 2026 in Review

Dodge & Cox increased its Neurocrine Biosciences (NBIX) stake by 2.3% in Q2 2026, buying an estimated $18.3M and bringing the position to 5,584,707 shares worth $941M. The position accounts for 0.49% of the portfolio, ranked #69.

Dodge & Cox first reported a position in NBIX in Q3 2023 and has held it in 12 quarters since. 774 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Dodge & Cox held 5,584,707 shares of Neurocrine Biosciences worth $941M as of Q2 2026.
  • Dodge & Cox bought 123,670 Neurocrine Biosciences shares in Q2 2026, an estimated $18.3M.
  • Neurocrine Biosciences made up 0.49% of Dodge & Cox's portfolio in Q2 2026, its #69 holding.
  • Dodge & Cox first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 12 quarters since.
  • 774 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Dodge & Cox's 13F filing for Q2 2026, filed 13 Aug 2026.